Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MITF | O75030 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CPB1 | P15086 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8279227 | 1.00 | MITF (0.48) | MITFMAPTHTTFKBP1ANPSR1 | |
| SCHEMBL2124213 | 0.88 | NPSR1 (0.48) | MITFMAPTHTTFKBP1ANPSR1 | |
| SCHEMBL703547 | 0.88 | SMN1; SMN2 (0.48) | NPSR1PREPSMN1; SMN2NPC1RAB9A | |
| SCHEMBL5765399 | 0.88 | SMN1; SMN2 (0.48) | NPSR1PREPSMN1; SMN2NPC1RAB9A | |
| SCHEMBL3471343 | 0.87 | PDK1 (0.44) | MITFMAPTHTTFKBP1APREP | |
| SCHEMBL16241249 | 0.87 | MITF (0.46) | MITFMAPTHTTFKBP1ANPSR1 | |
| SCHEMBL16241248 | 0.87 | MITF (0.46) | MITFMAPTHTTFKBP1ANPSR1 | |
| SCHEMBL16241371 | 0.87 | MITF (0.46) | MITFMAPTHTTFKBP1ANPSR1 | |
| SCHEMBL18020339 | 0.87 | MITF (0.49) | MITFMAPTHTTFKBP1ANPSR1 | |
| SCHEMBL4849095 | 0.86 | HTT (0.48) | MITFMAPTHTTFKBP1ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017186147-A1 | BENZIMIDAZOLE-LINKED INDOLE COMPOUND ACTING AS NOVEL DIVALENT IAP ANTAGONIST | 南京明德新药研发股份有限公司 | 2017-11-02 | — | — | WO | disclosed |
| EP-2368900-A2 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-28 | — | — | EP | disclosed |
| EP-2341065-A2 | Inhibitors of serine proteases, particularly HCV NS3-NS4a protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-06 | — | — | EP | disclosed |
| US-20110034449-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-02-10 | — | — | US | disclosed |
| US-20110034449-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-02-10 | — | — | US | disclosed |
| US-7820660-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2010-10-26 | — | — | US | disclosed |
| US-7820660-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2010-10-26 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20080275004-A1 | N-Substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | MSD ITALIA S.R.L. (IT) | 2008-11-06 | — | — | US | disclosed |
| US-20080275004-A1 | N-Substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | MSD ITALIA S.R.L. (IT) | 2008-11-06 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070123524-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | MSD ITALIA S.R.L. (IT) | 2007-05-31 | — | — | US | disclosed |
| US-20070123524-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | MSD ITALIA S.R.L. (IT) | 2007-05-31 | — | — | US | disclosed |
| US-7217713-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-05-15 | — | — | US | disclosed |
| US-7217713-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-05-15 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169780-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | ISTITUTE DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-01-30 | — | — | US | disclosed |
| US-7169780-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | ISTITUTE DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-01-30 | — | — | US | disclosed |
| WO-2005007681-A9 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | — | 2006-04-06 | — | — | WO | disclosed |
| WO-2005007681-A2 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275004-A1 | N-Substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | IMPDH1, REV1, CCNI | MITF 4672/4885MAPT 3986/4885HTT 3845/4885 |
| US-20110034449-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | IMPDH1, REV1, CCNI | MITF 4672/4885MAPT 3986/4885HTT 3845/4885 |
| US-20070123524-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | IMPDH1, REV1, CCNI | MITF 4672/4885MAPT 3986/4885HTT 3845/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | MITF 4776/4885MAPT 4113/4885HTT 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.